NCT03821246View on ClinicalTrials.gov

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Prostate AdenocarcinomaProstate CancerLocalized Prostate Cancer
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Tocilizumab

Given IV

DRUG

Etrumadenant

Given Orally

Trial Locations (2)

63110

RECRUITING

Alvin J. Siteman Cancer Center at Washington University, St Louis

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Arcus Biosciences, Inc.

INDUSTRY

lead

David Oh

OTHER

NCT03821246 - Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | Biotech Hunter | Biotech Hunter